ELISA Kit DIY Materials for Programmed Cell Death Protein 1 Ligand 1 (PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- Product No.KSA788Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Reagent Contents Capture Antibody, Detection Antibody, Standard, Streptavidin-HRP, TMB Substrate, 96-well Plate
- Detectable Sampleserum, plasma, tissue homogenates and other biological fluids
- Applicable PrincipleDouble-antibody Sandwich ELISA for Antigen Detection
- Detectable Range0.156-10ng/mL
- Applicable Sensitivity0.057ng/mL
- ApplicationsMain materials for "Do It (ELISA Kit) Yourself".
- DownloadInstruction Manual
- UOM 96T*596T*10 96T*20 96T*50 96T*100
For more details, please contact local distributors! US$ 1890
For more details, please contact local distributors! US$ 3402
For more details, please contact local distributors! US$ 6615
For more details, please contact local distributors! US$ 11340
For more details, please contact local distributors!
The Abs in the kit have high sensitivity and excellent specificity for detection of Programmed Cell Death Protein 1 Ligand 1 (PDCD1LG1). No significant cross-reactivity or interference between Programmed Cell Death Protein 1 Ligand 1 (PDCD1LG1) and analogues was observed.
1. Coat the plates with 100μL per well of working solution of Capture Antibody.incubate overnight at 4°C or incubate at 37°C for 2 hours.
2. Aspirate and wash 1 time.
3. Block the plates with 200 μL per well of working solution of Blocking Buffer. Incubate at 37°C for 1.5 hours.
4. Aspirate and wash 1 time. The plates are now ready for sample detection, the protocol is the same as regular ELISA.
Antibodies, Standard and Streptavidin-HRP should be stored at -20°C. TMB should be stored at 4°C. 96-well Plate could be stored at room temperature. The contents are valid for twelve months. They are stable for one month after opening when stored at 4°C.
|Chinese Journal of Cancer||Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications NCBI: PMC3937742|
|Leukemia.?||High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Pubmed:24732592|
|Diabetes?Metab Res Rev.||PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile Pubmed:24816853|
|Lancet Haematol||Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study PubMed: 26686046|
|Eur J Cancer.||High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Pubmed:27039170|
|Journal of Cancer Research and Clinical Oncology||Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer article:10.1007|
|Journal of Hematology & Oncology||PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma pubmed:27737703|
|Lung Cancer.||High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. pubmed:28212990|
|Oncotarget||Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. pubmed:27780932|
|Oncotarget||High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. pubmed:27105512|
|Oncotarget.||Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma pubmed:27566569|
|Cancer Immunol Immunother.||Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. pubmed:28349165|
|Leukemia||Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients leu2016385a|
|Medicine||Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. pubmed:28207525|
|Allergology International||Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients pubmed:27617656|
|Medicine||Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy PMC5319514|
|American Journal of Respiratory and Critical Care Medicine||Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) Pdf:10.1164|
|Clinical Lung Cancer||Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer Pubmed:29859759|
|Journal of Rheumatology||Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis Pubmed:29419471|
|Translational Oncology||High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma Pubmed:29698935|